Autor(es):Mostrar menos -

Ortega, Marina Mazzilli ; da Silva, Lais Teodoro ; Candido, Erika Donizetti ; Zheng, Yingying ; Tiyo, Bruna Tiaki ; Ferreira, Arthur Eduardo Fernandes ; Correa-Silva, Simone ; Scagion, Guilherme Pereira ; Leal, Fabyano Bruno ; Chalup, Vanessa Nascimento ; Valerio, Camila Araujo ; Schmitz, Gabriela Justamante Handel ; Ceneviva, Carina ; Cora, Aline Pivetta ; de Almeida, Alexandre ; Durigon, Edison Luiz ; Oliveira, Danielle Bruna Leal ; Palmeira, Patricia ; da Silva Duarte, Alberto Jose ; Carneiro-Sampaio, Magda ; Oshiro, Telma Miyuki

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 12, n. 1, p. 12-pg., 2022-06-16.

Resumo

We investigated the anti-SARS-CoV-2 post-vaccine response through serum and salivary antibodies, serum antibody neutralizing activity and cellular immune response in samples from health care workers who were immunized with two doses of an inactivated virus-based vaccine (CoronaVac) who had or did not have COVID-19 previously. IgA and IgG antibodies directed at the spike protein were analysed in samples of saliva and/or serum by ELISA and/or chemiluminescence assays; the neutralizing activity of serum antibodies against reference strain B, Gamma and Delta SARS-CoV-2 variants were evaluated using a virus neutralization test and SARS-CoV-2 reactive interferon-gamma T-cell were analysed by flow cytometry. CoronaVac was able to induce serum and salivary IgG anti-spike antibodies and IFN-gamma producing T cells in most individuals who had recovered from COVID-19 and/or were vaccinated. Virus neutralizing activity was observed against the ancestral strain, with a reduced response against the variants. Vaccinated individuals who had previous COVID-19 presented higher responses than vaccinated individuals for all variables analysed. Our study provides evidence that the CoronaVac vaccine was able to induce the production of specific serum and saliva antibodies, serum virus neutralizing activity and cellular immune response, which were increased in previously COVID-19-infected individuals compared to uninfected individuals. (AU)

• Processo FAPESP: 18/12460-0 - Produção e caracterização de células dendríticas polarizantes aDC1 para protocolo clínico de imunoterapia anti-HIV
• Beneficiário: Laís Teodoro da Silva
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 16/25212-9 - Vacina terapêutica baseada em células dendríticas aDC1 e vírus autólogo inativado visando o controle viral de indivíduos infectados pelo HIV-1 em interrupção de terapia antirretroviral
• Beneficiário: Alberto José da Silva Duarte
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 21/06139-7 - Caracterização e carregamento de antígenos relevantes de HIV em células dendríticas aDC1 para imunoterapia anti-HIV
• Beneficiário: Gabriela Justamante Handel Schmitz
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 19/24849-1 - Delivery de antígenos de HIV associados a nanopartículas: potencial aplicação na imunoterapia anti-HIV com células dendríticas derivadas de monócitos
• Beneficiário: Bruna Tiaki Tiyo
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 20/06409-1 - Avaliação da resposta imune humoral e da resposta inflamatória em pacientes com diagnóstico confirmado de COVID-19 no Hospital Sírio Libanês e correlação com a severidade da doença
• Beneficiário: Edison Luiz Durigon
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/50489-9 - O timo humano: desenvolvimento e doenças
• Beneficiário: Magda Maria Sales Carneiro-Sampaio
• Modalidade de apoio: Auxílio à Pesquisa - Temático